| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 15.984 | 16.013 | 14.582 | 11.579 | 11.742 | 14.050 | 17.577 | 15.056 | 14.767 | 19.920 |
| Total Income - EUR | 15.984 | 16.013 | 14.582 | 11.579 | 13.626 | 14.050 | 17.577 | 15.056 | 14.767 | 19.920 |
| Total Expenses - EUR | 13.235 | 18.942 | 17.040 | 12.530 | 12.692 | 13.753 | 8.165 | 7.067 | 10.145 | 20.103 |
| Gross Profit/Loss - EUR | 2.750 | -2.929 | -2.458 | -950 | 935 | 297 | 9.412 | 7.989 | 4.622 | -183 |
| Net Profit/Loss - EUR | 2.270 | -3.410 | -2.896 | -1.298 | 526 | 29 | 9.119 | 7.569 | 3.722 | -475 |
| Employees | 0 | 2 | 2 | 0 | 0 | 1 | 0 | 2 | 2 | 1 |
Check the financial reports for the company - Endogyn Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 17.447 | 29.303 | 18.696 | 12.401 | 6.774 | 2.260 | 495 | 109 | 34.690 | 57.757 |
| Current Assets | 167 | 742 | 97 | 1.415 | 491 | 577 | 2.635 | 10.356 | 517 | 1.134 |
| Inventories | 0 | 0 | 0 | 853 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.544 | 0 | 77 |
| Cash | 167 | 742 | 97 | 562 | 491 | 577 | 2.635 | 2.812 | 517 | 1.057 |
| Shareholders Funds | 177 | -3.235 | -6.076 | -7.261 | -6.595 | -6.441 | 2.821 | 7.612 | 3.790 | 3.370 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 17.438 | 33.280 | 24.868 | 21.077 | 13.860 | 9.277 | 309 | 2.853 | 31.417 | 55.522 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Endogyn Srl